Médicaments et grossesse en rhumatologie

@article{Elefant2010MdicamentsEG,
  title={M{\'e}dicaments et grossesse en rhumatologie},
  author={Elisabeth Elefant and M. P. Cournot and Delphine Beghin and Catherine Vauzelle},
  journal={Revue du Rhumatisme},
  year={2010},
  volume={77}
}

Exploratory study of risk factors for congenital malformations in Morocco

TLDR
The causes and risk factors of congenital malformations are diverse, which requires the application of large preventive and therapeutic approaches, however, the identification of risk factors specific to each country is necessary to establish specific preventive measures.

References

SHOWING 1-10 OF 55 REFERENCES

Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancy

  • I. UstaA. NassarK. YunisA. Abu‐musa
  • Medicine
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 2007

Methotrexate/misoprostol embryopathy: Report of four cases resulting from failed medical abortion

TLDR
Data from the patients herein described should prompt obstetricians and other health care practitioners who prescribe these medications to counsel their patients regarding these risks, especially if the treatment regimen fails to induce an abortion.

The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.

TLDR
Rheumatologists agree that there is a risk of teratogenicity with MTX and LF and usually require the use of reliable methods of birth control in women taking these medications.

[Fetal toxicity of non-steroidal anti-inflammatory agents].

TLDR
In obstetrical tocolysis NSAIDs can be given in the absence of alternative therapy with beta-adrenergic agents, and their risk can be minimized by ultrasonographic examination and monitoring of foetal cardiac function and diuresis.

Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome

TLDR
The fetus could have in utero exposure to leflunomide up to 2 years after the end of treatment unless an oral cholestyramine regimen, 8 g three times daily for 11 days, is administered to obtain undetectable plasmatic levels.

Birth outcomes in women who have taken leflunomide during pregnancy.

TLDR
The data do not support the notion that there is a substantial increased risk of adverse pregnancy outcomes due to leflunomide exposure among women who undergo cholestyramine elimination procedure early in pregnancy, and can provide some reassurance to women who inadvertently become pregnant while taking leflinomide and undergo the washout procedure.

Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature

TLDR
While case reports have limited value in identifying human teratogens, the unusual distribution of malformations among the 14 reported exposed offspring identifies a phenotype suggesting that MMF is likely ahuman teratogen.

In utero exposure to mycophenolate mofetil: A characteristic phenotype?

TLDR
It is concluded that in utero exposure to MMF can cause a characteristic phenotype and proposed the existence of a mycophenolate‐associated embryopathy whose main features are: cleft lip and palate, microtia with atresia of external auditory canal, micrognathia and hypertelorism.

Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases

TLDR
HCQ is not associated with any increased risk of congenital defects, spontaneous abortions, fetal death, pre-maturity and decreased numbers of live births in patients with auto-immune diseases.
...